DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy
Small Methods · 2023-05 · 7 (5)
DOI: 10.1002/smtd.202201518 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Methods, online erschienen am 18.01.2023. Verfasst von Run Tian und 4 weiteren Autor:innen. Beteiligte Einrichtung: CAS Key Laboratory of Nanosystem and Hierarchical Fabrication, CAS Center for Excellence in Nanoscience, National Center for NanoScience and Technolo…. Hauptthemen laut MEDLINE: Neoplasms, Nanostructures, Antineoplastic Agents. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 189 Literaturangaben. Gefördert von: National Key R&D Program of China National Basic Research Program of China, National Natural Science Foundation of China, Strategic Priority Research Program of Chinese Academy of Sciences.
Abstract (Originalsprache)
The past few decades have witnessed the evolving paradigm for cancer therapy from nonspecific cytotoxic agents to selective, mechanism‐based therapeutics, especially immunotherapy. In particular, the integration of nanomaterials with immunotherapy is proven to improve the therapeutic outcome and minimize off‐target toxicity in the treatment. As a novel nanomaterial, DNA‐based self‐assemblies featuring uniform geometries, feasible modifications, programmability, surface addressability, versatility, and intrinsic biocompatibility, are extensively exploited for innovative and effective cancer immunotherapy. In this review, the successful employment of DNA nanoplatforms for cancer immunotherapy, including the delivery of immunogenic cell death inducers, adjuvants and vaccines, immune checkpoint blockers as well as the application in immune cell engineering and adoptive cell therapy is summarized. The remaining challenges and future perspectives regarding the pharmacokinetics/pharmacodynamics, in vivo fate and immunogenicity of DNA materials, and the design of intelligent DNA nanomedicine for individualized cancer immunotherapy are also discussed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- CAS Key Laboratory of Nanosystem and Hierarchical Fabrication, CAS Center for Excellence in Nanoscience, National Center for NanoScience and Technology, Beijing, 100190, China.
- School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing, 100049, China.
- Sino-Danish College, Sino-Danish Center for Education and Research, University of Chinese Academy of Sciences, Beijing, 100049, China.
- School of Materials Science and Engineering, Zhengzhou University, Zhengzhou, 450001, China.
ORCID-Profile: Baoquan Ding
Förderung
- National Key R&D Program of China National Basic Research Program of China
- National Natural Science Foundation of China
- Strategic Priority Research Program of Chinese Academy of Sciences
- Youth Innovation Promotion Association, CAS
- CAS Interdisciplinary Innovation Team
- K. C. Wong Education Foundation
- CAS Project for Young Scientists in Basic Research
- Youth Innovation Promotion Association of the Chinese Academy of Sciences
Zitieren
APA
Tian, R., Shang, Y., Wang, Y., Jiang, Q., & Ding, B. (2023). DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy. Small Methods, 7(5). https://doi.org/10.1002/smtd.202201518
Vancouver
Tian R, Shang Y, Wang Y, Jiang Q, Ding B. DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy. Small Methods. 2023;7(5). doi:10.1002/smtd.202201518
BibTeX
@article{Tian2023,
author = {Tian, Run and Shang, Yingxu and Wang, Yiming and Jiang, Qiao and Ding, Baoquan},
title = {DNA Nanomaterials‐Based Platforms for Cancer Immunotherapy},
journal = {Small Methods},
year = {2023},
volume = {7},
number = {5},
doi = {10.1002/smtd.202201518}
}
EUVIMED